

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- **Name:** Yoon Kyung Jeon
  - **Current Position & Affiliation:** Professor, Seoul National University College of Medicine
  - **Country:** Republic of Korea
- 

 • **Educational Background:**

- 2000.3-2004.8 PhD, Pathology, Graduate School, Seoul National University College of Medicine, Seoul, Republic of Korea
- 1994.3-1998.2 M.D. Seoul National University College of Medicine, Seoul, Republic of Korea
- 1992.3-1994.2 Premedical Course, Seoul National University College of Natural Science, Seoul, Republic of Korea

 • **Professional Experience:**

- 2017.3-present Professor, Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
- 2012.3-2017.2 Clinical professor, Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea
- 2011.8-2012.12 Visiting scholar, University of Michigan Medical School, Ann Arbor, Michigan, USA
- 2003.11-2012.2 Clinical assistant professor, Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea
- 1999.3-2003.2 Resident in Pathology, Seoul Nat'l Univ. Hospital, Seoul, Republic of Korea

 • **Professional Organizations:**

- Member, Korean Society of Pathologists
- Member, Hematopathology Study Group of Korean Society of Pathologists
- Member, Korean Society of Hematology
- Member, Korean Association of Immunologists
- Member, American Association for Cancer Research
- Member, American Society of Hematology

 • **Main Scientific Publications:**

1. Yim J, Koh J, Kim S, Song SG, Bae JM, Yun H, Sung JY, Kim TM, Park SH, **Jeon YK**. Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing. Am J Surg Pathol. 2022 Jan 4.
2. Koh J, Jang I, Mun S, Lee C, Cha HJ, Oh YH, Kim JM, Han JH, Paik JH, Cho J, Ko YH, Park CS, Go H, Huh J, Kim K, **Jeon YK**. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021 Oct 26;5(20):3919-3930.

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

3. Han B, Kim S, Koh J, Yim J, Lee C, Heo DS, Kim TM, Paik JH, **Jeon YK**. Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort. *Cancers (Basel)*. 2020 Nov 9;12(11):3305.
4. Koh J, Jang I, Choi S, Kim S, Jang I, Ahn HK, Lee C, Paik JH, Kim CW, Lim MS, Kim K, **Jeon YK**. Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma. *Cancers (Basel)*. 2020 Jun 23;12(6):1669.
5. Kim S, Kwon D, Koh J, Nam SJ, Kim YA, Kim TM, Kim CW, **Jeon YK**. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. *Virchows Arch*. 2020 Jul;477(1):131-142.
6. Kim S, Jang JY, Koh J, Kwon D, Kim YA, Paeng JC, Ock CY, Keam B, Kim M, Kim TM, Heo DS, Chung DH, **Jeon YK**. Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. *J Exp Clin Cancer Res*. 2019 Nov 12;38(1):462.
7. Kim S, Nam SJ, Park C, Kwon D, Yim J, Song SG, Ock CY, Kim YA, Park SH, Kim TM, **Jeon YK**. High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. *Oncoimmunology*. 2019 Jun 10;8(9):e1626653.
8. Nam SJ, Kim S, Kwon D, Kim H, Kim S, Lee E, Kim TM, Heo DS, Park SH, Lim MS, Kim CW, **Jeon YK**. Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. *Oncoimmunology*. 2018 Mar 13;7(7):e1442164.
9. Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, Kim YA, Kim TM, Heo DS, Kim CW, Jeon YK. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. *Histopathology*. 2016 Jun;68(7):1079-89.